@Article{oncologie.2022.021863, AUTHOR = {Hangxing Wang, Jingyun Fang, Yujiao Wang, Shuo Li, Zirui Wang, Wei He, Nan Wang, Shuang Luo, Huimei Zou, Fan Zhang}, TITLE = {Gene Editing in Non-Small Cell Lung Cancer: Current Application and Future Perspective}, JOURNAL = {Oncologie}, VOLUME = {24}, YEAR = {2022}, NUMBER = {1}, PAGES = {65--83}, URL = {http://www.techscience.com/oncologie/v24n1/47264}, ISSN = {1765-2839}, ABSTRACT = {Lung cancer is the most common malignant tumor with the highest morbidity and mortality in the world, and non-small cell lung cancer (NSCLC) accounts for the vast majority of cases. At present, its main treatment methods are still traditional surgery, radiotherapy and chemotherapy, with disadvantages such as a high recurrence rate and limited effectiveness. Therefore, a new, better treatment method is urgently needed. Gene editing technology, as a new genetic engineering approach, has shown great potential in gene research, gene therapy and genetic improvement. It has also emerged as a promising treatment for lung cancer. This paper reviews the current research and applications of gene editing technology in NSCLC and other aspects of NSCLC, the therapeutic principle and mechanism of action, and the existing problems and prospects. This review aims to provide a basis for the prevention and treatment of NSCLC in the future and improve the survival rate of lung cancer patients.}, DOI = {10.32604/oncologie.2022.021863} }